Omicron variant neutralizing antibodies following BNT162b2 BA.4/5 versus mRNA-1273 BA.1 bivalent vaccination in patients with end-stage kidney disease

被引：6

作者：

Yau, Kevin ^{[1
,2
]}

Kurtesi, Alexandra ^{[3
]}

Qi, Freda ^{[3
]}

Delgado-Brand, Melanie ^{[3
]}

Tursun, Tulunay R. ^{[3
]}

Hu, Queenie ^{[3
]}

Dhruve, Miten ^{[4
]}

Kandel, Christopher ^{[5
]}

Enilama, Omosomi ^{[6
]}

Levin, Adeera ^{[7
]}

Jiang, Yidi ^{[8
]}

Hardy, W. Rod ^{[3
]}

Yuen, Darren A. ^{[9
]}

Perl, Jeffrey ^{[9
]}

Chan, Christopher T. ^{[2
]}

Leis, Jerome A. ^{[10
]}

Oliver, Matthew J. ^{[1
,11
]}

Colwill, Karen ^{[3
]}

Gingras, Anne-Claude ^{[3
,12
]}

Hladunewich, Michelle A. ^{[1
,11
]}

机构：

[1] Univ Toronto, Temerty Fac Med, Sunnybrook Hlth Sci Ctr, Div Nephrol,Dept Med, Toronto, ON, Canada

[2] Univ Toronto, Univ Hlth Network, Temerty Fac Med, Div Nephrol,Dept Med, Toronto, ON, Canada

[3] Sinai Hlth, Mt Sinai Hosp, Lunenfeld Tanenbaum Res Inst, Toronto, ON, Canada

[4] Michael Garron Hosp, Div Nephrol, Toronto, ON, Canada

[5] Michael Garron Hosp, Div Infect Dis, Toronto, ON, Canada

[6] Univ British Columbia, Div Expt Med, Dept Med, Vancouver, BC, Canada

[7] British Columbia Prov Renal Agcy, Vancouver, BC, Canada

[8] Sunnybrook Res Inst, Ctr Clin Trial Support, Toronto, ON, Canada

[9] Univ Toronto, Temerty Fac Med, Dept Med, Div Nephrol,Unity Hlth Toronto, Toronto, ON, Canada

[10] Univ Toronto, Temerty Fac Med, Sunnybrook Hlth Sci Ctr, Dept Med,Div Infect Dis, Toronto, ON, Canada

[11] Ontario Renal Network, Toronto, ON, Canada

[12] Univ Toronto, Dept Mol Genet, Toronto, ON, Canada

来源：

NATURE COMMUNICATIONS | 2023年 / 14卷 / 01期

基金：

加拿大健康研究院; 加拿大创新基金会;

关键词：

D O I：

10.1038/s41467-023-41678-9

中图分类号：

O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];

学科分类号：

07 ; 0710 ; 09 ;

摘要：

Neutralization of Omicron subvariants by different bivalent vaccines has not been well evaluated. This study characterizes neutralization against Omicron subvariants in 98 individuals on dialysis or with a kidney transplant receiving the BNT162b2 (BA.4/BA.5) or mRNA-1273 (BA.1) bivalent COVID-19 vaccine. Neutralization against Omicron BA.1, BA.5, BQ.1.1, and XBB.1.5 increased by 8-fold one month following bivalent vaccination. In comparison to wild-type (D614G), neutralizing antibodies against Omicron-specific variants were 7.3-fold lower against BA.1, 8.3-fold lower against BA.5, 45.8-fold lower against BQ.1.1, and 48.2-fold lower against XBB.1.5. Viral neutralization was not significantly different by bivalent vaccine type for wild-type (D614G) (P = 0.48), BA.1 (P = 0.21), BA.5 (P = 0.07), BQ.1.1 (P = 0.10), nor XBB.1.5 (P = 0.10). Hybrid immunity conferred higher neutralizing antibodies against all Omicron subvariants. This study provides evidence that BNT162b2 (BA.4/BA.5) and mRNA-1273 (BA.1) induce similar neutralization against Omicron subvariants, even when antigenically divergent from the circulating variant. Here the authors evaluate neutralizing antibodies following COVID-19 bivalent vaccination and find that both Pfizer BA.5 (BNT162b2) and Moderna BA.1 (mRNA-1273) vaccines elicit similar neutralization against Omicron subvariants BA.1, BA.5, BQ.1.1, and XBB.1.5 in patients with end-stage kidney disease.

引用

页数：8

共 50 条

[31] Improved cellular and humoral immunity upon a second BNT162b2 and mRNA-1273 boost in prime-boost vaccination no/low responders with end-stage renal disease
Stervbo, Ulrik
Blazquez-Navarro, Arturo
Blanco, Elena Vidal
Safi, Lema
Meister, Toni L.
Paniskaki, Krystallenia
Stockhausen, Mara
Marheinecke, Corinna
Zimmer, Gert
Wellenkoetter, Jacqueline
Giglio, Tina
Arora, Prerna
Poehlmann, Stefan
Hoffmann, Markus
Seibert, Felix S.
Pfaender, Stephanie
Roch, Toralf
Westhoff, Timm H.
Cinkilic, Okan
Babel, Nina
KIDNEY INTERNATIONAL, 2021, 100 (06) : 1335 - 1337
[32] Vaccine-induced humoral response of BNT162b2 and mRNA-1273 against BA.1, BA.5, and XBB.1.5. (sub)variants 6 months after a homologous booster: is immunogenicity equivalent?
Favresse, Julien
Tre-Hardy, Marie
Gillot, Constant
Cupaiolo, Roberto
Wilmet, Alain
Beukinga, Ingrid
Blairon, Laurent
Bayart, Jean-Louis
Closset, Melanie
Wauthier, Loris
Cabo, Julien
David, Clara
Elsen, Marc
Dogne, Jean-Michel
Douxfils, Jonathan
HELIYON, 2024, 10 (16)
[33] Bivalent BNT162b2 mRNA original/omicron BA.4-5 booster vaccination: adverse reactions and inability to work compared with the monovalent COVID-19 booster
Wagenhauser, Isabell
Reusch, Julia
Gabel, Alexander
Krone, Lukas B.
Kurzai, Oliver
Petri, Nils
Krone, Manuel
CLINICAL MICROBIOLOGY AND INFECTION, 2023, 29 (04) : 554 - 556
[34] Antibody response, neutralizing potency, and transplacental antibody transfer following SARS-CoV-2 infection versus mRNA-1273, BNT162b2 COVID-19 vaccination in pregnancy
Dude, Carolynn M.
Joseph, Naima T.
Forrest, Alexandra D.
Verkerke, Hans P.
Cheedarla, Narayanaiah
Govindaraj, Sakthivel
Irby, Les'Shon S.
Easley, Kirk A.
Smith, Alicia K.
Stowell, Sean R.
Neish, Andrew
Amara, Rama Rao
Jamieson, Denise J.
Dunlop, Anne L.
Badell, Martina L.
Velu, Vijayakumar
INTERNATIONAL JOURNAL OF GYNECOLOGY & OBSTETRICS, 2023, 162 (01) : 154 - 162
[35] BNT162b2 booster after heterologous prime-boost vaccination induces potent neutralizing antibodies and T cell reactivity against SARS-CoV-2 Omicron BA.1 in young adults
Seidel, Alina
Zanoni, Michelle
Gross, Ruediger
Krnavek, Daniela
Erdemci-Evin, Suemeyye
von Maltitz, Pascal
Albers, Dan P. J.
Conzelmann, Carina
Liu, Sichen
Weil, Tatjana
Mayer, Benjamin
Hoffmann, Markus
Poehlmann, Stefan
Beil, Alexandra
Kroschel, Joris
Kirchhoff, Frank
Muench, Jan
Mueller, Janis A.
FRONTIERS IN IMMUNOLOGY, 2022, 13
[36] Effectiveness of BNT162b2 BA.4/5 Bivalent COVID-19 Vaccine against Long COVID Symptoms: A US Nationwide Study
Di Fusco, Manuela
Sun, Xiaowu
Allen, Kristen E.
Yehoshua, Alon
Berk, Alexandra
Alvarez, Mary B.
Porter, Thomas M.
Ren, Jinma
Puzniak, Laura
Lopez, Santiago M. C.
Cappelleri, Joseph C.
VACCINES, 2024, 12 (02)
[37] Longitudinal data on humoral response and neutralizing antibodies against SARS-CoV-2 Omicron BA.1 and subvariants BA.4/5 and BQ.1.1 after COVID-19 vaccination in cancer patients
Oliver Overheu
Simon Lendowski
Daniel R. Quast
Daniel Kühn
Elena Vidal Blanco
Anna-Lena Kraeft
Eike Steinmann
Eleni Kourti
Celine Lugnier
Joerg Steinmann
Anke Reinacher-Schick
Stephanie Pfaender
Journal of Cancer Research and Clinical Oncology, 2023, 149 : 10633 - 10644
[38] Effectiveness of BNT162b2 BA.4/5 Bivalent mRNA Vaccine Against Symptomatic COVID-19 Among Immunocompetent Individuals Testing at a Large US Retail Pharmacy
Rudolph, Abby E.
Khan, Farid L.
Shah, Amy
Singh, Tanya G.
Wiemken, Timothy L.
Puzniak, Laura A.
Jodar, Luis
McLaughlin, John M.
JOURNAL OF INFECTIOUS DISEASES, 2024, 229 (03): : 648 - 659
[39] Longitudinal data on humoral response and neutralizing antibodies against SARS-CoV-2 Omicron BA.1 and subvariants BA.4/5 and BQ.1.1 after COVID-19 vaccination in cancer patients
Overheu, Oliver
Lendowski, Simon
Quast, Daniel R.
Kuehn, Daniel
Blanco, Elena Vidal
Kraeft, Anna-Lena
Steinmann, Eike
Kourti, Eleni
Lugnier, Celine
Steinmann, Joerg
Reinacher-Schick, Anke
Pfaender, Stephanie
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2023, 149 (12) : 10633 - 10644
[40] Neutralizing antibodies to SARS-CoV-2 variants of concern including Delta and Omicron in subjects receiving mRNA-1273, BNT162b2, and Ad26.COV2.S vaccines
Zhang, George Fei
Meng, Wen
Chen, Luping
Ding, Ling
Feng, Jian
Perez, Joseph
Ali, Abid
Sun, Shenyu
Liu, Zhentao
Huang, Yufei
Guo, Haitao
Gao, Shou-Jiang
JOURNAL OF MEDICAL VIROLOGY, 2022, 94 (12) : 5678 - 5690

← 1 2 3 4 5 →